RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma

M. Imbimbo, M. Vitali, A. Fabbri, M. Ottaviano, G. Pasello, I. Petrini, G. Palmieri, R. Berardi, P. Zucali, M. Ganzinelli, M. Marabese, M. Broggini, M. Marino, A. Trama, E. Rulli, L. Hollander, G. Pruneri, V. Torri, M.C. Garassino

Research output: Contribution to journalArticlepeer-review

Cite this